AT₁-Rezeptor-Blocker und ACE-Hemmer in Kombination – pro

Schlüsselwörter

ACE-Hemmer - AT₁-Rezeptor-Blocker - arterielle Hypertonie - Renin-Angiotensin-Blockade - Proteinurie - Niereninsuffizienz

Keywords

ACE inhibition - angiontensin receptor blocker - arterial hypertension - renin-angiotensin system - proteinuria - renal failure

Literatur

• 1 Hovind P, Rossing P, Tarnow L, Smidt U M, Parving H H. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively.  Kidney Int. 2001;  60 277-283
• 2 Keane W F, Brenner B M, de Zeeuw D. et al . The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.  Kidney Int. 2003;  63 1499-1507
• 3 Mann J F, Schmieder R E, McQueen M. et al . Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.  Lancet. 2008;  372 547-553
• 4 The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). . Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric nephropathy.  Lancet. 1997;  349 1857-1863
• 5 Yusuf S, Teo K K, Pogue J. et al . Telmisartan, ramipril, or both in patients at high risk for vascular events.  N Engl J Med. 2008;  358 1547-1559
• 6 de Zeeuw D, Remuzzi G, Parving H H. et al . Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.  Kidney Int. 2004;  65 2309-2320